[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 77, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1122237, "exercisedValue": 0, "unexercisedValue": 51427864}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 70, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 813077, "exercisedValue": 4094829, "unexercisedValue": 35092304}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 841238, "exercisedValue": 0, "unexercisedValue": 3954412}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 913742, "exercisedValue": 0, "unexercisedValue": 17441960}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Strategy & Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 23.39, "open": 23.59, "dayLow": 22.79, "dayHigh": 23.805, "regularMarketPreviousClose": 23.39, "regularMarketOpen": 23.59, "regularMarketDayLow": 22.79, "regularMarketDayHigh": 23.805, "payoutRatio": 0.0, "beta": -0.032, "forwardPE": -12.486773, "volume": 691383, "regularMarketVolume": 691383, "averageVolume": 845203, "averageVolume10days": 791770, "averageDailyVolume10Day": 791770, "bid": 16.92, "ask": 29.2, "bidSize": 2, "askSize": 2, "marketCap": 2649595648, "fiftyTwoWeekLow": 14.06, "fiftyTwoWeekHigh": 27.29, "priceToSalesTrailing12Months": 56.20695, "fiftyDayAverage": 19.81, "twoHundredDayAverage": 20.69915, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1841500032, "profitMargins": 0.0, "floatShares": 54899238, "sharesOutstanding": 112271000, "sharesShort": 6878437, "sharesShortPriorMonth": 6970274, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.061300002, "heldPercentInsiders": 0.00386, "heldPercentInstitutions": 1.11319, "shortRatio": 7.07, "shortPercentOfFloat": 0.0731, "impliedSharesOutstanding": 112271000, "bookValue": 6.93, "priceToBook": 3.4054835, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -187358000, "trailingEps": -1.84, "forwardEps": -1.89, "enterpriseToRevenue": 39.064, "enterpriseToEbitda": -9.713, "52WeekChange": 0.3681159, "SandP52WeekChange": 0.16932249, "quoteType": "EQUITY", "currentPrice": 23.6, "targetHighPrice": 53.1791, "targetLowPrice": 27.161482, "targetMeanPrice": 42.093567, "targetMedianPrice": 42.751617, "recommendationMean": 1.46154, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 808476992, "totalCashPerShare": 7.201, "ebitda": -189582000, "totalDebt": 389000, "quickRatio": 19.8, "currentRatio": 19.977, "totalRevenue": 47140000, "debtToEquity": 0.05, "revenuePerShare": 0.465, "returnOnAssets": -0.18146999, "returnOnEquity": -0.31511, "grossProfits": 47140000, "freeCashflow": -98995504, "operatingCashflow": -140430000, "revenueGrowth": 1.126, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -23.14473, "financialCurrency": "USD", "symbol": "NAMS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "NewAmsterdam Pharma Company N.V.", "shortName": "NewAmsterdam Pharma Company N.V", "regularMarketChangePercent": 0.897824, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1753475355, "regularMarketTime": 1753473600, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "postMarketChangePercent": 0.0, "postMarketPrice": 23.6, "postMarketChange": 0.0, "regularMarketChange": 0.210001, "regularMarketDayRange": "22.79 - 23.805", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 845203, "fiftyTwoWeekLowChange": 9.54, "fiftyTwoWeekLowChangePercent": 0.6785206, "fiftyTwoWeekRange": "14.06 - 27.29", "fiftyTwoWeekHighChange": -3.6900005, "fiftyTwoWeekHighChangePercent": -0.13521437, "fiftyTwoWeekChangePercent": 36.811592, "earningsTimestamp": 1746707400, "earningsTimestampStart": 1754569800, "earningsTimestampEnd": 1754569800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.84, "epsForward": -1.89, "epsCurrentYear": -1.58542, "priceEpsCurrentYear": -14.885646, "fiftyDayAverageChange": 3.790001, "fiftyDayAverageChangePercent": 0.19131757, "twoHundredDayAverageChange": 2.9008503, "twoHundredDayAverageChangePercent": 0.14014345, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-07-25", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "regularMarketPrice": 23.6, "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-07-26"}]